Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
The receptor-binding domain (RBD) in SARS-CoV-2 S protein was identified and it was found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors and could block the binding and, hence, attachment of SARs-Cov-2 RBD and SARS -CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells.
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
- Ke Wang, Wei Chen, Zhi-Nan Chen
- Biology, MedicineSignal Transduction and Targeted Therapy
- 1 December 2020
A novel virus entry route, CD147-spike protein, is revealed, which provides an important target for developing specific and effective drug against COVID-19.
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
A neutralizing monoclonal antibody, which targets the receptor-binding domain of Middle East respiratory syndrome (MERS) coronavirus spike, mediates viral entry using pseudovirus entry and biochemical assays, and results showed that MAb binds to the virus surface spike, allowing it to undergo conformational changes and become prone to proteolytic activation.
Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
A mouse model in which a SARS-CoV-2 strain was infectious and could cause an inflammatory response and moderate pneumonia is developed, and a panel of adaptive mutations potentially associated with the increased virulence are revealed.
Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV
It is found that MERS-CoV infection induced pyroptosis and over-activation of complement in human macrophages and inflammation was suppressed by inhibiting C5aR1.
A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
This study proves the feasibility of producing cost-effective, potent, and broad-spectrum Nbs against MERS-CoV and has produced Nbs with great potentials as anti-MERS- coV therapeutics.
A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity
A short-lipopeptide-based fusion inhibitor, termed LP-19, is developed which mainly targets the conserved gp41 pocket site and shows highly potent inhibitory activity against HIV-1, HIV-2, and even SIV isolates.
Sensitive and Easy-Read CRISPR Strip for COVID-19 Rapid Point-of-Care Testing.
An easy- readout and sensitive enhanced ERASE strip is developed to visualize the results of CRISPR detection and improve the sensitivity to 1 copy/μL with an unambiguous easy-read result for SARS-CoV-2 detection.
Generation and Characterization of a Nanobody Against SARS-CoV
A novel nanobody targeting SARS-CoV RBD is developed, which might be useful for the development of therapeutics against SARS.
Rapid adaptation of SARS-CoV-2 in BALB/c mice: Novel mouse model for vaccine efficacy
It is found that mouse-adapted SARS-CoV-2 at passage 6 (MACSp6) efficiently infected both aged and young wild-type BALB/c mice, resulting in moderate pneumonia as well as inflammatory responses.